SENSHIO

This brand name is authorized in Austria, Croatia, Estonia, Ireland, Italy, Lithuania, Poland, Singapore, Spain, UK.

Active ingredients

The drug SENSHIO contains one active pharmaceutical ingredient (API):

1	Ospemifene UNII B0P231ILBK - OSPEMIFENE
	Ospemifene and its major metabolite have an oestrogen like effect in the vagina increasing the cellular maturation and mucification of the vaginal epithelium. Ospemifene’s biological actions are mediated through the binding of ospemifene and its major metabolite to oestrogen receptors leading to activation of some oestrogenic pathways (agonism) and blockade of other (antagonism).
	Read more about Ospemifene

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SENSHIO Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G03XC05		G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03X Other sex hormones and modulators of the genital system → G03XC Selective estrogen receptor modulators
Discover more medicines within G03XC05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1676178, 1676189, 1766190
ES	Centro de información online de medicamentos de la AEMPS	114978002
GB	Medicines & Healthcare Products Regulatory Agency	357248
IT	Agenzia del Farmaco	043868013, 043868025, 043868037
LT	Valstybinė vaistų kontrolės tarnyba	1075826, 1075827, 1084613
PL	Rejestru Produktów Leczniczych	100338167
SG	Health Sciences Authority	15568P